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Abstract
Background: PTEN (phosphatase and tensin homologue deleted on chromosome ten) is a tumor suppressor gene
implicated in a wide variety of human cancers, including glioblastoma. PTEN is a major negative regulator of the PI3K/Akt
signaling pathway. Most human gliomas show high levels of activated Akt, whereas less than half of these tumors carry
PTEN mutations or homozygous deletions. The unique ability of mesenchymal stem cells to track down tumor cells makes
them as potential therapeutic agents. Based on this capability, new therapeutic approaches have been developed using
mesenchymal stem cells to cure glioblastoma. However, molecular mechanisms of interactions between glioma cells and
stem cells are still unknown.
Methodology/Principal Findings: In order to study the mechanisms by which migration of glioma cells can be inhibited by
the upregulation of the PTEN gene, we studied two glioma cell lines (SNB19 and U251) and two glioma xenograft cell lines
(4910 and 5310) alone and in co-culture with human umbilical cord blood-derived mesenchymal stem cells (hUCBSC). Co-
cultures of glioma cells showed increased expression of PTEN as evaluated by immunofluorescence and immunoblotting
assays. Upregulation of PTEN gene is correlated with the downregulation of many genes including Akt, JUN, MAPK14, PDK2,
PI3K, PTK2, RAS and RAF1 as revealed by cDNA microarray analysis. These results have been confirmed by reverse-
transcription based PCR analysis of PTEN and Akt genes. Upregulation of PTEN resulted in the inhibition of migration
capability of glioma cells under in vitro conditions. Also, wound healing capability of glioma cells was significantly inhibited
in co-culture with hUCBSC. Under in vivo conditions, intracranial tumor growth was inhibited by hUCBSC in nude mice.
Further, hUCBSC upregulated PTEN and decreased the levels of XIAP and Akt, which are responsible for the inhibition of
tumor growth in the mouse brain.
Conclusions/Significance: Our studies indicated that upregulation of PTEN by hUCBSC in glioma cells and in the nude mice
tumors downregulated Akt and PI3K signaling pathway molecules. This resulted in the inhibition of migration as well as
wound healing property of the glioma cells. Taken together, our results suggest hUCBSC as a therapeutic agent in treating
malignant gliomas.
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Introduction
Despite many advances in the treatment of malignant
glioblastoma via surgery, radiotherapy and chemotherapy,
patients afflicted with this disease continue to have a very poor
prognosis [1–3]. Malignant glioblastoma is characterized by rapid
cell proliferation, high invasion and genetic alterations [4–6]. A
number of genetic alterations are involved in oncogenesis,
including deactivation of tumor suppressor genes such as PTEN
(phosphatase and tensin homologue deleted on chromosome ten)
[7]. PTEN is a tumor suppressor gene implicated in a wide variety
of human cancers and is a major negative regulator of the PI3K/
Akt signaling pathway. Most human glioblastomas show high
levels of activated Akt, whereas less than half carry PTEN
mutations or homozygous deletions. There are several lines of
evidence implicating PTEN in the regulation of cellular migration
and invasion. It has also been suggested that PTEN may regulate
cell migration by directly dephosphorylating FAK in the DBTRG-
05MG glioblastoma cell line [8]. PTEN plays a significant role in
inducing G1 cell cycle arrest and apoptosis, along with regulating
cell adhesion, migration and differentiation [9,10]. Dey et al. [11]
studied glioma cell migration on vitronectin, which binds avb3
integrin, and showed that PTEN’s protein phosphatase activity
negatively regulated RAC1 indirectly by regulating the activity of
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gliomas include the finding that tyrosine kinase receptors and
signal transduction pathways play a role in tumor initiation and
maintenance [12]. PTEN is a tumor suppressor with phosphatase
activity in vitro against both lipids and proteins and other potential
non-enzymatic mechanisms of action. Davidson’s recent data
provides a novel tool to address the significance of PTEN’s
separable lipid and protein phosphatase activities and suggests that
both activities suppress proliferation and both activities are
required in concert to achieve efficient inhibition of invasion
[13]. However, it is not clear whether PTEN genuinely regulates
cell migration, tumor invasiveness and metastasis in vivo using the
mechanisms and pathways defined by in vitro systems [14].
Recent studies have indicated that mesenchymal stem cells
(MSCs) have the capacity to target therapeutic genes to malignant
glioma [15–17]. Human umbilical cord blood is a rich source of
both hematopoietic stem cells and MSCs [18,19]. Stem cells
derived from umbilical cord show higher proliferation and
expansion potential than adult bone marrow stem cells [20,21].
Human umbilical cord-derived mesenchymal stem cells
(hUCBSC) have been regarded as an alternative cell source for
cell transplantation and cell therapy because of their hematopoi-
etic and non-hematopoietic (mesenchymal) potential [19,22,23].
To study the mechanisms by which migration of glioma cells can
be inhibitedby the upregulation of PTEN gene, we used two glioma
cell lines (SNB19 and U251) and two glioma xenograft cell lines
(4910 and 5310) alone and in co-culture with hUCBSC. We
evaluated whether hUCBSC are capable of inhibiting the migration
capability of glioma cells both in vitro and in vivo, and whether this
effect is mediated by downregulation of the PI3K-Akt pathway.
Results
Co-culture of glioma cells with hUCBSC upregulates
PTEN
For all the experiments of this study, we used hUCBSC which are
positiveforCD29 and CD81,asconfirmed byimmunocytochemistry
and FACS analyses (data not shown). To evaluate the efficiency of
hUCBSC, we tested the effect of hUCBSC on glioma cells in co-
cultures. All of the four glioma cell lines of the present study were co-
cultured with hUCBSC for 3 days and the total RNA was extracted
and reverse-transcribed to cDNA. We ran cDNA microarrays for
PI3K-Akt pathway as described in Materials and Methods. We found
that PTENis upregulated many times over inthefour tested cell lines.
Many genes related to PI3K-Akt pathway were downregulated in
SNB19, U251 and 4910 cells, whereas most of the genes in5310 cells
were brought down to normal levels. The upregulation of PTEN
gene was correlated with the downregulation of numerous genes
including Akt, JUN, MAPK14, PDK2, PI3K, PTK2, RAS and
RAF1 as revealed by cDNA microarrays (Table 1). To check for
PTEN expression levels, we carried out immunofluorescence assays
with the PTEN antibody and found that with hUCBSC treatment,
significant upregulation of PTEN took place in all of the glioma cells
in the present study (Fig. 1A). This indicates that hUCBSC
upregulated PTEN in glioma cells. To confirm these results, we
checked the expression of PTEN, Akt and PI3K at both the
transcriptional and translational levels. In both cases, PTEN was
upregulated in hUCBSC-treated cancer cells whereas Akt, phospho-
Akt and PI3K were downregulated as compared to control cells
(Figs. 1B and 1C). To evaluate whether hUCBSC undergo any
changes after co-culturing with glioma cells, hUCBSC were grown in
conditioned media of glioma cells and observed for changes in PTEN
expression at both transcriptional and translational levels. We did not
observe any significant changes in the levels of PTEN in hUCBSC
grown in glioma conditioned media (Figs. 1D and 1E). These results
confirmthat hUCBSC upregulates PTEN in gliomacellsand shows a
negative effect on PI3K and Akt levels as well as the phosphorylation
status of the Akt
Ser473 molecules.
Conditioned media from co-cultured glioma and hUCBSC
inhibits spheroid migration
To determine the effects of PTEN upregulation in glioma cells,
we performed the spheroid migration assay using conditioned
Table 1. Effect of hUCBSC on glioma cells after co-culture (cDNA microarray results of PI3K-AKT pathway).
Gene Description
Fold up or down regulation
SNB19 U251 5310 4910
AKT1/PKB V-akt murine thymoma viral oncogene homolog 1 24.53 22.35 21.12 24.00
FOXO1 Forkhead box O1 23.43 23.81 1.03 26.96
JUN Jun oncogene 218.13 23.10 22.01 213.93
MAPK14 Mitogen-activated protein kinase 14 21.72 23.32 21.69 210.56
P110 (PIK3CA) Phosphoinositide-3-kinase, catalytic, alpha polypeptide 27.89 1.77 1.14 26.06
P27, KIP I (CDKN1B) Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 24.23 21.30 1.45 210.56
PAK1 P21 protein (Cdc42/Rac)-activated kinase 1 238.85 23.43 1.06 213.00
PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 1.09 25.39 21.08 1.52
PDK2 Pyruvate dehydrogenase kinase, isozyme 2 241.64 210.06 21.47 248.50
PI3K (PIK3CG) Phosphoinositide-3-kinase, catalytic, gamma polypeptide 26.87 21.26 1.61 24.29
PIK3R2 Phosphoinositide-3-kinase, regulatory subunit 2 (beta) 213.74 24.08 1.67 222.63
PTEN Phosphatase and tensin homolog 7.06 2.17 2.13 3.73
PTK2 PTK2 protein tyrosine kinase 2 211.16 22.35 21.01 216.00
RAS (RASA1) RAS p21 protein activator (GTPase activating protein) 1 219.43 21.66 1.36 25.66
RAF1 V-raf-1 murine leukemia viral oncogene homolog 1 215.78 25.98 22.08 24.00
Human PI3K-Akt PCR arrays (SA Biosciences) were run using cDNA from single and co-cultures of glioma cells with hUCBSC. Real time PCR was carried out and changes
in gene expression were illustrated as a fold increase/decrease according to manufacturer’s instructions. The cut-off induction determining expression was 2.0 or 22.0
fold changes. Genes that met these criteria were considered to be upregulated or downregulated.
doi:10.1371/journal.pone.0010350.t001
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model is a three-dimensional cell culture system that more closely
resembles the in vivo situation inside a tumor [24]. Spheroid
growth reflects the proliferation of tumor cells, while the
migration assay measures the ability of the cells organized in a
three-dimensional structure to migrate and proliferate [25]. The
cell migration away from the spheroid was monitored over a
period of 24 h to 48 h by photographing the mid plane of the
spheroids at intervals of 24 h with an inverted Olympus phase
contrast microscope. In conditioned media of untreated glioma
cells, the cells from spheroids started migrating as early as 24 h,
whereas in conditioned media of co-cultures, spheroid migration
was delayed significantly, even after 48 h (Fig. 2A). We observed
that spheroid migration was significantly inhibited in 5310 cells
(51.19%) followed by 4910 (47.86%), U251 (41.95%) and SNB19
(41.4%) cells (Fig. 2B). In order to prove that PTEN is responsible
for the inhibition of spheroid migration, glioma cells were grown
in conditioned media from single and co-cultures. Similar to co-
culture cell lysates, glioma cells grown in conditioned media also
showed upregulated PTEN (Fig. 2C). In another experiment,
spheroids were transfected with siRNA to PTEN (siPTEN) and
then grown in conditioned media from co-cultures. We did not
observe any significant change in the inhibition of spheroid
migration (Figs. S1A and S1B). These results prove that
upregulation of PTEN in glioma cells by conditioned media
from co-cultured glioma and hUCBSC cells inhibit spheroid
migration.
Inhibition of the wound healing capacity of glioma cells
by hUCBSC
Glioma cells, in general, have very good wound healing
capacity. In order to evaluate the effect of hUCBSC on wound
healing, we checked the wound healing capacity of glioma cells in
single cultures and co-cultures with hUCBSC. A wound was made
in a sub-confluent cell monolayer and cells were allowed to
migrate into the cell-free area. The distance moved by the cells in
control and co-cultured plates, respectively, was compared. The
mobility of glioma cells was inhibited in co-cultures compared to
single cultures. We observed that SNB19 and U251 cells repair
their wounds in 8 h; 4910 cells heal in 9 h and 5310 cells heal in
Figure 1. Upregulation of PTEN in hUCBSC-treated co-cultures of glioma cells. (A) Fluorescent microscopic images demonstrate PTEN
expression (red fluorescence). SNB19, U251, 4910 and 5310 cells were co-cultured with hUCBSC for 3 days and processed for immunofluorescence.
Immunostaining was performed with Alexa flour-594 conjugated PTEN antibodies. All sections were stained with DAPI to show nuclear localization.
Insets show DAPI. n $ 3. Scale bar =100 mm. (B) Equal amounts of protein (40 mg) from single cultures and co-cultures were loaded onto 12% SDS
gels and transferred onto nitrocellulose membranes, which were then probed with respective antibodies. GAPDH was used as a positive loading
control. (C) Reverse transcription-based PCR analysis of PTEN, Akt and PI3K in co-cultures. b-actin was used as a positive loading control. Each blot
and gel is representative of experiments performed in duplicate with each sample (n=3). hUCBSC were grown in conditioned media from hUCBSC
(control), SNB19, U251, 4910 and 5310 conditioned media for 3 days and the lysates (80 mg for each lane) were subjected to (D) Western analysis for
PTEN or (E) Reverse-transcription based PCR analysis. CM= conditioned medium.
doi:10.1371/journal.pone.0010350.g001
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capacity (Fig. 3A). The wound healing capacity is significantly
inhibited in 4910 cells (63.75%) as compared to U251 (53.74%),
5310 (50.99%) and SNB19 (49.99%) cells (Fig. 3B). In order to
confirm, whether inhibition of wound healing is by soluble factors
present in the conditioned media of co-cultures or due to cell-to-
cell contact between glioma cells and hUCBSC, we performed
another experiment with conditioned media from single cultures
and co-cultures. Compared to complete media, glioma cells took
long time to repair the wounds in conditioned media. For
example, in SNB19 cells wound healing was observed after 23 h in
conditioned medium compared to 8 h in complete medium.
Similarly, wound healing was complete after 24 h in U251, after
21 h in 4910 and after 22 h in 5310 cells. However, glioma cells
grown in hUCBSC conditioned medium and co-cultured
conditioned medium did not show any inhibition of wound
healing (Fig. S2A and S2B). Overall, these results indicate that
cell-to-cell contact between hUCBSC and glioma cells is necessary
which significantly decreased wound healing capacity of glioma
cells.
Upregulation of PTEN by hUCBSC treatment has an anti-
tumor effect in U251 and 5310 glioma nude mice models
Our in vitro experiments have proved that co-culture with
hUCBSC can efficiently inhibit glioma cell migration and wound
healing capacity. Therefore, we further investigated the anti-tumor
effect of these stem cells in vivo using U251 and 5310 cells in nude
mice. After the mice were implanted with U251, 5310 and
hUCBSC as described in Materials and Methods, the mice were
observed for 21 days. At that point, tumor samples were taken,
and paraffin-embedded sections were prepared for immunohisto-
pathological examination. Hematoxylin and Eosin (H&E) staining
of the in vivo sections clearly showed that the tumors in hUCBSC-
treated mice were inhibited significantly and were one-third of the
Figure 2. Conditioned medium from co-culture of glioma cells with hUCBSC inhibits spheroid migration. (A) SNB19, U251, 4910 and
5310 cells were cultured in 96-well low attachment plates at a concentration of 5610
4 cells, and spheroids were allowed to grow for 24 h at 37uC with
shaking at 40–60 rpm. The spheroids were then transferred to 48-well plates and maintained for another 24–48 h in conditioned media from single
cultures and co-cultures. Spheroid migration was analyzed using a phase-contrast microscope. Scale bar =1000 mm. (B) Quantitative analysis of
spheroid migration from (A). Error bars indicate SEM. *p ,0.05. **p ,0.01. n=3. (C) Immunoblot analysis of PTEN from glioma cells grown in their
respective control conditioned media and co-culture conditioned media.
doi:10.1371/journal.pone.0010350.g002
Stem Cells Upregulate PTEN
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cultures and co-cultures with hUCBSC. They were allowed to grow at 37uCi n5 %C O 2 atmosphere. Every three hours, cells that had migrated to the
wounded areas were photographed under a microscope for quantification of cell migration. Images are representative of three separate experiments.
Stem Cells Upregulate PTEN
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were much bigger in size and more invasive than 5310 tumors.
Next, we checked for the presence of hUCBSC in tumor areas of
the brains of both control and hUCBSC-treated mice brain
sections by immunofluorescence. In hUCBSC-treated mice brain
tissue, the presence of hUCBSC as confirmed by mesenchymal
stem cells markers CD29 and CD81, clearly establishes the fact
that hUCBSC are responsible for tumor size reduction observed in
the hUCBSC-treated brains (Figs. 4B and 4C). These CD29 and
CD81 positive cells were observed in tumor regions only. We
could not detect them in normal areas of the brains. Further, we
evaluated PTEN expression in nude mice brain sections by
colocalization studies using PTEN and CD81 antibodies. Nude
mice brains treated with hUCBSC clearly show that PTEN was
highly upregulated in hUCBSC-treated mice (Fig. 4C). CD81 was
observed in hUCBSC-treated mice sections only and they were
absent in control tumor sections. Colocalization of PTEN and
CD81 in hUCBSC-treated mice confirms that the upregulation of
PTEN was the result of presence of hUCBSC. It is plausible that
hUCBSC not only upregulated PTEN in glioma cells which are in
contact with them but also in surrounding glioma cells. We also
evaluated whether upregulation of PTEN in mice brains had any
effect on X-linked inhibitor of apoptosis protein (XIAP) levels in
tumor brains. For this, we did DAB immunohistochemistry on
both control tumor and stem cell-treated brains. Tumor brains
show high levels of XIAP expression, whereas hUCBSC-treated
brains show reduced levels of XIAP expression (Fig. 4D). This
confirms that upregulation of PTEN in tumors significantly
decreased the levels of XIAP as to induce the cellular death of
the glioma cells.
Further, to understand the molecular mechanisms of PTEN-
induced tumor regression, we evaluated the tissue lysates of both
control tumor brains and hUCBSC-treated tumor brains by
immunoblotting. Similar to the in vitro results, the expression levels
of PTEN is upregulated, whereas Akt, p-Akt, FAK and XIAP in
tumor specimens from hUCBSC-treated mice were prominently
downregulated (Fig. 5A). Next, we assessed the mRNA expression
of PTEN, XIAP, FAK and PDGFR. All of these genes were highly
downregulated after the hUCBSC treatment with the upregulation
of PTEN (Figs. 5C and 5D).
Scale bar =500 mm. (B) Quantitative analysis of wound-induced migration assay from (A). The results are presented as mean 6 SEM of three
experiments done in duplicate. *p ,0.05. **p ,0.001.
doi:10.1371/journal.pone.0010350.g003
Figure 4. Inhibition of intracranial tumors by hUCBSC in vivo. (A) Nude mice with pre-established intracranial human glioma tumors (U251 or
5310) were treated with hUCBSC by intracranial injection (2.5610
5). Fourteen days after hUCBSC administration, the brains were harvested, sectioned,
and stained with Hematoxylin and Eosin (n$3). Inset pictures show higher magnification at scale bar =100 mm. (B) Characterization of hUCBSC in
tumor areas in nude mice brain sections: Fourteen days after hUCBSC administration, the brains were harvested, sectioned and immunoprobed with
mesenchymal stem cell markers CD29 and CD81 using Alexa flour-594 secondary antibody. (n $ 3). Scale bar =100 mm. (C) Upregulation of PTEN in
nude mice: Mice brain sections were immunoprobed with PTEN and CD81 using appropriate fluorescence-conjugated secondary antibodies.
Secondary antibodies used for PTEN and CD81 were: goat anti-mouse Alexa flour-594 for PTEN and donkey anti-goat Alexa Fluor 488 for CD81,
respectively. Scale bar =100 mm. (D) Downregulation of XIAP in mice: Mice brain sections were probed with XIAP antibody by DAB
immunohistochemistry and counterstained with DAPI. Scale bar =100 mm. Inset pictures show DAPI. (n =.3).
doi:10.1371/journal.pone.0010350.g004
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human cancers, including glioblastoma, because of loss of
PTEN. Deletion or loss of PTEN function leads to failure to
convert PIP3 back to PIP2, resulting in the deregulation of
PI3K in the absence of upstream signals from receptor tyrosine
kinases. Hence, we determined to check the expression of
proteins related to the PI3K/Akt pathway (e.g., PI3K, RhoA,
RAC1, CDC42 and PDGFR). We found that all were
downregulated in mice brains treated with hUCBSC (Fig. 5B),
showing that PTEN upregulation is inhibiting the PI3K/Akt
pathway, thereby regulating the growth of tumor cells. These
results confirm the anti-tumor effect of hUCBSC in vivo and
that tumor cell migration in vivo is efficiently regulated by
hUCBSC.
Figure 5. In vivo expression of PTEN and other signaling proteins. Equal amounts of protein (40 mg) from tissue lysates of untreated and
treated mice brains were loaded onto 10–14% SDS gels and transferred onto nitrocellulose membranes, which were then probed with respective
antibodies. GAPDH was used as a positive loading control. (A) PTEN, Akt, pAkt, FAK and XIAP proteins with respect to GAPDH. (B) Western blot
analysis of PI3K pathway related proteins. (C) Reverse transcription-based PCR analysis of PTEN, XIAP, FAK and PDGFR in brain tissue lysates. Each blot
or gel is representative of experiments performed in duplicate with each sample (n=3). (D) Real-Time PCR analysis of FAK, PTEN, XIAP and PDGFR
genes of in vivo samples. n=3. Error bars indicate SEM. *p ,0.05.
doi:10.1371/journal.pone.0010350.g005
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Malignant glioblastoma is a highly invasive tumor of the central
nervous system. Currently available therapies offer only limited
benefit for patients with glioblastoma. As such, there is an
immediate necessity to develop new therapeutic approaches and
to better understand the molecular pathogenesis of glioblastoma.
PTEN mediates many of its effects on proliferation, growth, survival
andmigration throughitsPtdIns(3,4,5)P3lipidphosphataseactivity,
suppressing phosphoinositide 3-kinase (PI3K)-dependent signaling
pathways [26]. Re-expression of PTEN in mammalian cells lacking
the enzyme has been found to inhibit the motility of several lineages
ofsuch cells,includingmouseembryofibroblastsand tumor-derived
cells of glial and prostate origin [8,27,28], although most of these
studies have not addressed the mechanism of action of PTEN. In
this study, we investigated the effects of hUCBSC on the effects of
migration of glioma cells by upregulation of PTEN. We observed
that the stem cells are able to upregulate PTEN simultaneously
downregulating the PI3K/Akt pathway and inhibiting the growth
and migration of the cancer cells.
The Akt signaling pathway is very important in glioblastoma
multiforme (GBM) progression, and this pathway is activated in
the majority of primary GBM samples [29,30] as well as in
xenografts derived from GBM tumor samples [31]. Akt represents
a nodal point in cell signaling and can be activated by several
upstream events, including epidermal growth factor receptor
amplification or mutation, loss of PTEN, and PIK3CA mutation.
As such, targeting this pathway may be able to block glioblastoma
multiforme proliferation secondary to a variety of upstream
etiologies [32]. We observed a similar rate of Akt pathway
activation in all four GBM cell lines used in this study (Fig. 1).
When these glioma cells are co-cultured with hUCBSC,
upregulation of PTEN has been observed with concomitant
downregulation of Akt and phosphorylated form of Akt.
Phosphatidyl-inositol-3-kinase (PI3K) can phosphorylate and
activate Akt while PI3K is negatively regulated by the tumor
suppressor gene PTEN, which has been shown to be non-
functional in 20 to 40% of GBM [33–36]. Akt is over-activated in
many glioblastomas due to the loss of PTEN function [37,38]. Akt
regulates the function of numerous downstream signaling proteins
involved in cell cycle, proliferation, apoptosis and invasion, which
are all important to tumorigenesis [39]. Activated Akt deregulates
cell growth by stabilization of cyclin D and promotion of the
nuclear entry of MDM2, leading to the degradation of p53 [40].
Akt might also inhibit p21 expression through its phosphorylation
and activation of MDM2 and subsequent downregulation of p53-
mediated transcription of p21 [41,42]. On the other hand,
activated Akt exerts anti-apoptotic activity by phosphorylating and
inactivating pro-apoptotic signaling proteins, such as BAD and
caspase 9 [39,43]. The involvement of Akt in diverse tumorigenic
activities suggests that Akt activation alone might be sufficient to
induce cancer [44]. Moreover, Akt activation may contribute to
tumor invasion/metastasis by stimulating secretion of matrix
metalloproteinases [45]. Therefore, dysregulation of the PI3K/Akt
signaling pathway may play an important role in tumor
development and progression.
In the present study, hUCBSC are able to upregulate PTEN
under both in vitro and in vivo conditions. This upregulation of
PTEN decreased the expression of Akt and its phosphorylated
form pAkt. Also, hUCBSC treatment resulted in the downregu-
lation of XIAP, which is highly upregulated in glioma cells, both in
vitro and in vivo. This in turn resulted in the dysregulation of PI3K/
Akt signaling pathway and ultimately inhibited the survival of
glioma cells. In addition, hUCBSC treatment downregulated
PDGFR and Akt genes at the transcriptional and translational
levels, this resulted in the inhibition of glioma migration. In order
to understand the anti-cancer effect of hUCBSC, we examined
their effect on migration and wound healing capacity of glioma
cells. Through our experiments, we confirmed that hUCBSC
effect on glioma cells decreased the levels of phosphorylated Akt,
which alters both cell migration and wound healing capacity.
Tumor invasion requires both tumor cell migration and the
degradation of the extracellular matrix [46]. Cell motility is one of
the crucial points of metastasis which is necessary for the tumor
cell to move through the matrix and enter the circulation so that it
can travel to a distant site [47]. In our study, we demonstrated that
hUCBSC significantly reduced the migration of glioma cells from
the spheroids (Fig. 2). Wound-healing assays showed a slower
wound-closure following co-culture with hUCBSC treatment,
indicating decreased glioma cell motility (Fig. 3).
In our studies, we observed that PTEN upregulation accompa-
nied XIAP downregulation. Previous studies support a role for
XIAP in negatively regulating PTEN content in vitro and in vivo
[48]. Decrease of XIAP protein levels in colon cancer cells in
response to the apoptosis-inducing agent mesalazine is accompa-
nied, among others, by an increase of PTEN content [49].
Exposure of mice to the apoptosis-inducing agent rosiglitazone
modestly upregulates PTEN protein levels in HCT116-XIAP
+/+
cell-derived tumors but markedly increases PTEN content in
HCT116-XIAP
2/2 cell-derived tumors [50]. Recently, it was
proposed that XIAP acts as an E3 ubiquitin ligase for PTEN and
promotes Akt activity by regulating PTEN content and compart-
mentalization [48]. Akt is one of the anti-apoptotic factors that
must be activated through phosphorylation. The phosphorylation
of Akt has previously been shown to be promoted by XIAP,
another anti-apoptotic protein dictating the fate of normal and
cancer cells [51,52]. Our results are in accordance with the
previous reports that downregulation of XIAP did result in the
downregulation of Akt and inhibition of glioma cell growth.
Activation of PI3K occurs commonly in cancers including
glioblastoma, the most common primary brain tumor. Activation
of PI3K is associated with increased metabolism, suggesting
potential dependence of cancer cells on PI3K signaling, and raising
the possibility that blockade of PI3K signaling in glioma should
effectively kill these cells [53]. PTEN encodes a phosphatase that
dephosphorylates phosphatidylinositol-3,4,5 triphosphate to con-
vert it to phosphatidylinositol-4, 5 bisphosphate. Therefore,
inactivation of PTEN leads to increased levels of phosphatidylino-
sitol-3,4,5 triphosphate and increased Akt activation [33]. Con-
versely, restoration of PTEN leads to inhibition of Akt. Recently, it
was reported that survival times were significantly reduced in
patients whose tumors showed PI3K pathway activation [54]. In
our study with hUCBSC, we observed that PTEN upregulation
decreases levels of PI3K and its associated signaling molecules,
alongwith increasedAktinactivation.Thisultimatelyresulted inthe
regression of tumor growth in nude mice brains.
There have been no reports regarding the possible mechanisms
by which hUCBSC are capable of upregulating PTEN in glioma
cells. In our in vivo studies we observed that CD81, a mesenchymal
stem cell marker, is co-localized with PTEN in glioma regions of
the brain. This suggests that hUCBSC are in contact with the
glioma cells and are able to upregulate PTEN in glioma cells in
their vicinity. These results support previous reports from our
laboratory, which show that cell-to-cell contact between hUCBSC
and glioma cells is necessary to induce apoptosis in glioma cells by
hUCBSC (58). Taken together, our results demonstrate that
PTEN is an important component of the PI3K/Akt signaling
pathway. The growth retardation of glioblastoma cells treated with
Stem Cells Upregulate PTEN
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healing capability, but also due to the downregulation of Akt and
PI3K pathway-related genes. Targeting PTEN using hUCBSC
may be an effective new strategy for the molecular therapy of
human cancers.
Materials and Methods
Ethics Statement
After obtaining informed consent, human umbilical cord blood
was collected from healthy volunteers according to a protocol
approved by the Peoria Institutional Review Board, Peoria, IL,
USA. The consent was written and approved. The approved
protocol number is 06–014, dated December 10, 2009. The
Institutional Animal Care and Use Committee of the University
Of Illinois College Of Medicine at Peoria, Peoria, IL, USA
approved all surgical interventions and post-operative animal care.
The consent was written and approved. The approved protocol
number is 851, dated November 20, 2009.
Culture of glioma cell lines
Two high-grade human glioma cell lines (SNB19 and U251)
and two xenograft cell lines (4910 and 5310) were used for this
study. SNB19 and U251 cells lines were obtained from American
Type Culture Collection (ATCC, Manassas, VA). Two xenograft
cell lines (4910 and 5310) were kindly provided by Dr. David
James at University of California, San Francisco. SNB19 and
U251 cells were grown in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin in a humidified atmosphere containing 5%
CO2 at 37uC. Xenograft cell lines (4910 and 5310) were grown in
RPMI1640 medium supplemented with 10% fetal bovine serum
and 1% penicillin-streptomycin in a humidified atmosphere
containing 5% CO2 at 37uC. For all the cells, medium was
replaced every 2 days. In experiments with conditioned medium,
medium was replaced every day.
Isolation and culture of hUCBSC
After obtaining informed consent, human umbilical cord blood
was collected from healthy volunteers according to a protocol
approved by the Peoria Institutional Review Board, Peoria, IL,
USA. Human umbilical cord blood was enriched by sequential
Ficoll density gradient purification. Next, we selected cells using
CD29
+ and CD81
+ markers as described previously [55]. Briefly,
the nucleated cells were suspended at a concentration of 1610
6/
mL in Mesencult medium (Stem cell Technologies, Vancouver,
Canada) supplemented with 20% fetal bovine serum (FBS)
(Hyclone, Logan, UT), 1% penicillin-streptomycin (Invitrogen,
Carlsbad, CA) and plated in 100-mm culture dishes. The cells
were incubated for three days and the non-adherent cells were
removed with medium replacement. After the cultures reached
confluency, the cells were lifted by incubation with 0.25% trypsin
and 1 mM ethylene diamine tetraacetic acid (EDTA) at 37uC for 3
to 4 min. Cells were diluted at a ratio of 1:3 and replated and
cultured at 37uC in an incubator with a 5% CO2 atmosphere. For
co-culture experiments, hUCBSC and glioma cells were cultured
at a ratio of 1:4. Co-cultures were grown in the medium in which
single glioma cells were grown. For all the cells, medium was
replaced every 2 days. In experiments with conditioned medium,
medium was replaced every day.
Spheroid migration assay
Spheroid migration was assayed as described previously [56]
with some modifications. Spheroids of SNB19, U251, 5310 and
4910 cells were prepared by seeding a suspension of 5610
4 cells in
their respective media on ultra low attachment 96-well plates and
cultured until spheroid aggregates formed. Single glioma spheroids
were placed in the center of each well of a 0.5% agarose-coated
48-well microplate and 200 mL of conditioned media of single
cultures and co-cultures with hUCBSC was added to each well.
Spheroids were incubated at 37uC for 48 h, after which the
spheroids were fixed and stained with Hema-3 (Fisher Scientific,
Pittsburgh, PA) and photographed. The migration of cells from
spheroids to monolayers was quantified using a microscope
calibrated with a stage and ocular micrometer and represented
graphically.
Transfection of siPTEN
The glioma cells were cultured as mentioned previously. siRNA
to PTEN was obtained from Cell Signaling Technology (Danvers,
MA). Cells at 60–70% confluency in 100 mm tissue culture plates
were transfected with 100 nM of siPTEN and control siRNA using
Fugene HD as per manufacturer’s instructions (Roche, Indiana-
polis, IN). Following transfection, after 60–72 h depending on the
cell line, cell lysates were assessed for expression levels of PTEN
using western blot analysis as per standard protocols.
Wound healing assay
These experiments were done in either single and co-cultures in
complete media or in conditioned media of single and co-cultures.
Glioma cells (1610
6) were seeded in a 100-mm culture plate and
then cultured to at least 95% confluence. In a similar fashion,
glioma cells were co-cultured with hUCBSC. Monolayer cells were
washed with their respective media and then scraped with a plastic
200 mL pipette tip and then placed back in a 37uC incubator. The
‘‘wounded’’ areas were photographed by phase contrast micros-
copy at various time points (0, 3, 6, 8, 9, 10, 12, 21, 22, 23 and
24 h after scraping) depending on the cell line. The relative
migration distance was calculated by the following formula: the
relative migration distance (%)=100 (A–B)/A, where A is the
width of cell wounds before incubation, and B is the width of cell
wounds after incubation. Results are expressed as the mean 6
SEM.
Immunocytochemistry
Cultured hUCBSC were checked for mesenchymal markers by
immunocytochemistry. Cultured cells plated in 2-well chamber
slides were rinsed twice with phosphate buffered saline (PBS) and
fixed in 4% paraformaldehyde. After additional PBS rinses, cells
were blocked with 0.1 M PBS with 1% bovine serum albumin
(BSA) for 1 h. Primary antibodies (1:100 dilutions) specific for
mesenchymal markers: mouse anti-CD29 (Millipore, Danvers,
MA) and goat anti-CD81 (Santa Cruz Biotechnology, Santa Cruz,
CA) and primary antibody specific for PTEN were diluted in goat
serum and applied overnight at 4uC. Texas-Red conjugated anti-
mouse or anti-goat secondary antibodies were diluted (1:200) in
goat serum and applied individually for 1 to 2 h at room
temperature. Before mounting, the cells were stained with 49,6 -
diamidino-2-phenylindole (DAPI). The cells were observed using a
fluorescence microscope (Olympus IX71, Olympus, Melville, NY)
and/or a confocal microscope (Olympus Fluoview, Olympus,
Melville, NY) and photographed.
RNA extraction and quantitative real time PCR
All primer sequences were determined using established human
GenBank sequences. Primer sequences were designed using
Primer3 software (v.0.4.0). For real time polymerase chain
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analysis (RT
2 Profiler PCR Array, SuperArray, Frederick, MD),
total RNA was isolated from control and hUCBSC-treated cancer
cells. Total cellular RNA was extracted using RNeasy kit (Qiagen,
Valencia, CA), and RNA quality was determined by running a
sample with RNA loading dye on a 1% agarose gel and checking
for distinct 18S and 28S rRNA bands, indicating lack of
degradation. Quantity of RNA was determined by A260 measure-
ment. We used RNA whose A260:A280 ratio is greater than 2.0.
Samples were either used immediately or frozen at 280uC until
use in RT-PCR. Total RNA was reverse transcribed into first
strand cDNA using Transcriptor First Strand cDNA Synthesis Kit
(Roche, Indianapolis, IN). Each cDNA was tested by running
PCR using GAPDH and b-actin primers as a control for assessing
PCR efficiency and for subsequent analysis by 2% agarose gel
electrophoresis. PCR amplification was performed using the
primer sets, amplified by 35 cycles (94uC, 1 min; 60uC, 1 min;
72uC, 1 min) of PCR using 20 pM of specific primers. Further
quantitative analysis of genes was done by SYBR green based real-
time PCR using Bio-Rad iCycler iQ Real-Time PCR Detection
System. Each sample was measured in triplicate and normalized to
the reference GAPDH or b-actin gene expression. The value of
each well was determined and the average of the three wells of
each sample was calculated. For samples that showed no
expression of the test gene, the value of minimum expression
was used for statistical analysis. Delta CT (DCT) and DDCT values
were calculated and the fold change in the test gene expression was
finally calculated. A statistical evaluation of real-time PCR results
was performed using one-way analysis of variance (ANOVA) to
compare test gene expression between cancer cells and their co-
cultures with hUCBSC.
Primers used for PCR
FAK Sense 59ggtgcaatggagcgagtatt39
Antisense 59gccagtgaacctcctctga39
PTEN Sense 59ccaggaccagaggaaacct39
Antisense 59gctagcctctggatttga39
Akt Sense 59catcacaccacctgaccaa39
Antisense 59ctcaaatgcacccgagaaat39
PI3K Sense 59cccctccatcaacttcttca39
Antisense 59cggttgcctactggttcaat39
XIAP Sense 59ggccagactatgcccattta39
Antisense 59cgaagaagcagttgggaaa39
PDGFR Sense 59ctctgacggccatgagtaca39
Antisense 59catgatcttcagctccgaca39
b-Actin Sense 59gtcgtaccactggcattgt39
Antisense 59cagctgtggtggtgaagct39
cDNA microarray analysis
We used PI3K-Akt pathway finder RT2 Profiler PCR Array
(SuperArray Biosciences, Frederick, MD) because of its advantage
of real-time PCR performance combined with the ability of
microarrays to detect the expression of many genes simultaneous-
ly. Each array contains a panel of 96 primer sets of 84 relevant,
pathway-focused genes, plus five housekeeping genes and three
RNA and PCR quality controls. Real-time PCR was carried out
under the following conditions: one cycle of 95uC for 10 min, 40
cycles of 95uC for 15 sec and 60uC for 1 min. Data were exported
to Excel files and analyzed using SuperArray RT
2 Profiler PCR
Array Data Analysis Template (v3.0). Relative gene expression
levels were calculated based on the ratio of the mean of
housekeeping signals of all experiments. The formula used to
calculate the relative gene expression level (2 ‘ (-D Ct)) in the
‘‘Results’’ worksheet is: D Ct = Ct (GOI) – avg. (Ct (HKG)),
where GOI is each gene of interest, and HKG are the
housekeeping genes chosen for the ‘‘Sample-Control Gene’’
worksheet. Scatter plots were made from normalized signals.
Changes in gene expression were illustrated as a fold increase/
decrease. The cut-off induction determining expression was 2.0 or
22.0 fold changes. Genes, which met these criteria, were
considered to be upregulated or downregulated. We performed
these experiments in duplicate.
Immunoblot analysis of proteins
Single and co-cultures of glioma cells or nude mice brain tissues
were harvested and homogenized in four volumes of homogeni-
zation buffer (pH 7.4; 250 mM sucrose, 10 mM HEPES, 10 mM
Tris-HCl, 10 mM KCl, 1% NP-40, 1 mM NaF, 1 mM Na3VO4,
1 mM EDTA, 1 mM DTT, 0.5 mM PMSF plus protease
inhibitors: 1 mg/mL pepstatin, 10 mg/mL leupeptin and 10 mg/
mL aprotinin) using a Teflon-fitted glass homogenizer. The
homogenate was centrifuged at 20,000 g for 15 min at 4uC, and
the protein levels in the supernatant were determined using the
BCA assay (Pierce, Rockford, IL). Samples (40–50 mg of total
protein/well) were subjected to 10–14% SDS-PAGE and
transferred onto nitrocellulose membranes. The following anti-
bodies were used for Western blot analysis: mouse anti-PTEN
(1:200; Santa Cruz Biotechnology Inc, Santa Cruz, CA), mouse
anti-Fak (1:500; Santa Cruz Biotechnology Inc), goat PI3K (1:500;
Santa Cruz Biotechnology Inc.), mouse anti-XIAP (1:5000; BD
Biosciences, Franklin Lakes, New Jersey), rabbit anti-AKT
(1:1000; Cell Signaling Technology), mouse anti-phospho-AKT
(Ser
473) (1:1000; Cell Signaling Technology) mouse anti-Rho-A
(1:200; Santa Cruz Biotechnology Inc), rabbit anti-CDC42
[Phospho-Rac1/cdc42 (Ser
71) antibody (1:1000; Cell Signaling
Technology)], mouse anti-PDGFR (1:1000; Cell Signaling Tech-
nology), and mouse anti-RAC1(1:1000; BD Biosciences). The
membranes were blocked with 5% nonfat skim milk in PBS for 1 h
at room temperature and then incubated with primary antibodies
overnight at 4uC. The membranes were then processed with
horse-radish peroxidase (HRP)-conjugated secondary antibodies.
Immunoreactive bands were visualized using chemiluminescence
ECL Western blotting detection reagents (Amersham, Piscataway,
NJ). Immunoblots were stripped and re-developed with GAPDH
antibody [mouse anti-GAPDH (1:1000; Novus Biologicals,
Littleton, CO)] to ensure equal loading levels. Experiments were
performed in triplicates. Values for treated and untreated samples
were compared using one-way ANOVA. A p value of ,0.05 was
considered significant.
Intracranial tumor growth
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria, Peoria, IL,
USA approved all surgical interventions and post-operative animal
care. U251 (1610
6 cells) and 5310 (8610
5 cells) tumor cells were
intracerebrally injected into the right side of the brains of nude
mice, as described previously [57]. Seven days after tumor
implantation, the mice were injected with hUCBSC near the left
side of the brain. The ratio of the hUCBSC to cancer cells was
maintained at 1:4. Three weeks after tumor inoculation, six mice
from each group were sacrificed by cardiac perfusion with 4%
formaldehyde in PBS, their brains were removed, and paraffin
sections were prepared. Sections were stained with H&E to
visualize tumor cells and to examine tumor volume. The sections
were blind reviewed by a neuropathologist and scored semiquan-
titatively for tumor size. Whole-mount images of brains were also
taken to determine infiltrative tumor morphology. The average
tumor area per section integrated to the number of sections where
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volumes were compared between controls and treated groups. RT-
PCR was done on fresh brain tissue for FAK, PTEN, XIAP,
PDGFR and b-actin.
Immunohistochemical analysis
Brains of control and hUCBSC-treated mice brains were fixed
in formaldehyde and embedded in paraffin as per standard
protocols. Sections were deparaffinized as per standard protocol.
Sections were blocked in 1% BSA in PBS for 1 h, and the sections
were subsequently transferred to primary antibody diluted in 1%
BSA in PBS (1:100). Sections were allowed to incubate in the
primary antibody solution overnight at 4uC in a humidified
chamber. Sections were then washed in 1% BSA in PBS,
incubated with the appropriate secondary antibody for 1 h and
visualized using a confocal microscope. Transmitted light images
were obtained after H&E staining as per standard protocol to
visualize the morphology of the sections. For immunofluorescence,
sections were treated with primary antibodies overnight at 4uC
and then treated with appropriate Alexa flour secondary
antibodies at room temperature for 1 h. Negative controls were
maintained either without primary antibody or using IgG.
Statistical analysis
Quantitative data from cell counts, Western blot analysis, and
other assays were evaluated for statistical significance using one-
way analysis of variance (ANOVA). Data for each treatment group
were represented as mean 6 SEM and compared with other
groups for significance by one-way ANOVA followed by
Bonferroni’s post hoc test (multiple comparison tests) using Graph
Pad Prism version 3.02, a statistical software package. Results were
considered statistically significant at a p value less than 0.05.
Supporting Information
Figure S1 Spheroid migration in siPTEN transfected spheroids.
(A) SNB19, U251, 4910 and 5310 cells were cultured in 96-well
low attachment plates at a concentration of 5610
4 cells, and
spheroids were allowed to grow for 24 h at 37uC with shaking at
40–60 rpm. The spheroids were then transferred to 48-well plates
and were transfected with siPTEN for 60 h and then grown in
conditioned medium from co-cultures and maintained for another
24–48 h. Spheroid migration was analyzed using a phase-contrast
microscope. Scale bar=1000 mm. (B) Quantitative analysis of
spheroid migration from (A). Error bars indicate SEM. n=3.
Control=without any treatment and grown in glioma conditioned
media; siPTEN=transfected with siPTEN and grown in glioma
conditioned media; siPTEN + (Glioma cells +hUCBSC)=
transfected with siPTEN and grown in conditioned media from
glioma cells + hUCBSC.
Found at: doi:10.1371/journal.pone.0010350.s001 (7.50 MB TIF)
Figure S2 Monolayer wound-induced migration assay in
conditioned media. A line was scratched with a 200-mm plastic
pipette tip in SNB19, U251, 4910 and 5310 cultures. They were
allowed to grow at 37uCi n5 %C O 2 atmosphere in conditioned
media of glioma cells, hUCBSC and co-cultures. Every three
hours, cells that had migrated to the wounded areas were
photographed under a microscope for quantification of cell
migration. Images are representative of three separate experi-
ments. Scale bar =500 mm. (B) Quantitative analysis of wound-
induced migration assay from (A). The results are presented as
mean 6 SEM of three experiments done in duplicate. CM =
conditioned medium.
Found at: doi:10.1371/journal.pone.0010350.s002 (7.93 MB TIF)
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